final analysis of the GioTag study
Maximilian J Hochmair (Author), Alessandro Morabito (Author), Desiree Hao (Author), Cheng-Ta Yang (Author), Ross A Soo (Author), James C-H Yang (Author), Rasim Gucalp (Author), Balazs Halmos (Author), Angela Märten (Author), Tanja Čufer (Author)

Abstract

Aim: Final overall survival (OS) and time on treatment analysis of patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC) who received sequential afatinib and osimertinib. Patients & methods: Patients (n = 203) had T790M-positive disease following first-line afatinib and started osimertinib treatment >/=10 months before data entry. Primary outcome was time on treatment; OS analysis was exploratory. Results: Median time on treatment with afatinib and osimertinib was 27.7 months (90% CI: 26.7-29.9). Median OS was 37.6 months (90% CI: 35.5-41.3); median OS was 41.6 and 44.8 months in Del19-positive patients and Asian patients, respectively. Conclusion: In real-world clinical practice, sequential afatinib and osimertinib was associated with encouraging outcomes in patients with EGFR mutation-positive NSCLC, especially in Del19-positive patients and Asian patients.

Keywords

osimertinib;raziskava GioTag;GioTag study;

Data

Language: English
Year of publishing:
Typology: 1.01 - Original Scientific Article
Publisher: Future Medicine Ltd
UDC: 616-006
COBISS: 37424899 Link will open in a new window
ISSN: 1744-8301
Views: 902
Downloads: 645
Average score: 0 (0 votes)
Metadata: JSON JSON-RDF JSON-LD TURTLE N-TRIPLES XML RDFA MICRODATA DC-XML DC-RDF RDF

Other data

Secondary keywords: Carcinoma, non-small cell lung;Therapy;Drug therapy;Afatinib;Nedrobnocelični karcinom pljuč;Terapija;Terapija z zdravili;
Source comment: Nasl. z nasl. zaslona; Opis vira z dne 14. 11. 2020; Soavtorica iz Slovenije: Tanja Cufer;
Pages: str. 2799-2808
Volume: ǂVol. ǂ16
Issue: ǂiss. ǂ34
Chronology: Dec. 2020
DOI: 10.2217/fon-2020-0740
ID: 12168688